Alunbrig (BRIGATINIB)
Alunbrig (BRIGATINIB) is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: Alunbrig; Generic name: BRIGATINIB; Drug class: Kinase Inhibitor [EPC].
| Brand name | Alunbrig |
|---|---|
| Generic name | BRIGATINIB |
| Drug class | Kinase Inhibitor [EPC] |
| Manufacturer | Takeda Pharmaceuticals America, Inc. |
| Used for | 1 INDICATIONS AND USAGE ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . ALUNBRIG is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. ( 1 , 2.1 ) |
| Dosage | 2 DOSAGE AND ADMINISTRATION 90 mg orally once daily for the first 7 days; then increase to 180 mg orally once daily. May be taken with or without food. ( 2.2 ) 2.1 Patient Selection Select patients for the treatment of metastatic NSCLC with ALUNBRIG based on the presence of ALK positivity in tumor specimens [see Clinical Studies (14) ] . Information on FDA-approved tests for the detection of ALK rearrangements in NSCLC is available at http://www.fda.gov/CompanionDiagnostics. 2.2 Recommended Dosa |
| Active ingredient(s) | BRIGATINIB |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0fe9ff20-d402-41f3-bc1e-7002ea7007db |